has entered a to develop a new innovative therapy pipeline.
The parties will make an investment of $50m each to assess prospects for developing ten single-asset programmes.
The companies will utilise Flagship鈥檚 ecosystem of more than 40 human health firms and biotechnology platforms.
will hold the option to buy each chosen development programme.
Flagship and its bioplatform firms are entitled to receive milestone and royalty payments of up to $700m for each programme that successfully enters the market.
A Flagship Pioneering initiative, Pioneering Medicines, is partnering with the research and development leadership of Pfizer and will oversee the discovery process to aid in quick portfolio development.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe research will focus on addressing unmet needs within the key areas of interest to Pfizer.
Flagship Pioneering executive partner and Pioneering Medicines president Paul Biondi stated: 鈥淔lagship and Pfizer enter this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients.
鈥淭his new partnership brings together the best of our organisations to maximise discovery and development potential from inception to impact through a unique innovation supply chain that sets us on a path to potentially realise transformational medicines more quickly and effectively.鈥�
Pfizer made an investment of $25m in genome-editing biopharmaceutical company in July 2023.
